ArticleAngiogenesis2017
Tissue factor is an angiogenic-specific receptor for factor VII-targeted immunotherapy and photodynamic therapy.
Article in Angiogenesis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Role of angiogenesis in adenomyosis-associated abnormal uterine bleeding and subfertility: a systematic review.Human reproduction update · 2019Pooled it
- Optimization of a Western blot protocol for the detection of low levels of tissue factor in human cells.Research and practice in thrombosis and haemostasis · 2025Article
- Photodynamic Therapy in the Treatment of Cancer-The Selection of Synthetic Photosensitizers.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Editorial: Angiogenesis and access to vasculature as a target in gastrointestinal tumors and predictive biomarkers identification: an open challenge.Frontiers in oncology · 2024Article
- Procoagulant Activity of Umbilical Cord-Derived Mesenchymal Stromal Cells' Extracellular Vesicles (MSC-EVs).International journal of molecular sciences · 2023Article
- Current Challenges and Opportunities of Photodynamic Therapy against Cancer.Pharmaceutics · 2023Review
- Rethinking the potential and necessity of drug delivery systems in neovascular age-related macular degeneration therapy.Frontiers in bioengineering and biotechnology · 2023Review
- Tissue factor as a new target for tumor therapy-killing two birds with one stone: a narrative review.Annals of translational medicine · 2022Review
- CB1 receptor antagonist rimonabant protects against chronic intermittent hypoxia-induced renal injury in rats.BMC nephrology · 2021Article
- Current Targets and Bioconjugation Strategies in Photodynamic Diagnosis and Therapy of Cancer.Molecules (Basel, Switzerland) · 2020Review
- A Multi-Omics Approach Identifies Key Regulatory Pathways Induced by Long-Term Zinc Supplementation in Human Primary Retinal Pigment Epithelium.Nutrients · 2020Article
- Divergent Impact of Breast Cancer Laterality on Clinicopathological, Angiogenic, and Hemostatic Profiles: A Potential Role of Tumor Localization in Future Outcomes.Journal of clinical medicine · 2020Article
- Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer.Scientific reports · 2020Article
- Vascular targeted photodynamic therapy: A review of the efforts towards molecular targeting of tumor vasculature.Journal of porphyrins and phthalocyanines · 2019Article
- Matrine has pro-apoptotic effects on liver cancer by triggering mitochondrial fission and activating Mst1-JNK signalling pathways.The journal of physiological sciences : JPS · 2019Article
- Mst1 deletion attenuates renal ischaemia-reperfusion injury: The role of microtubule cytoskeleton dynamics, mitochondrial fission and the GSK3β-p53 signalling pathway.Redox biology · 2019Article
- Melatonin Attenuates Cardiac Reperfusion Stress by Improving OPA1-Related Mitochondrial Fusion in a Yap-Hippo Pathway-Dependent Manner.Journal of cardiovascular pharmacology · 2019Article
- Tissue factor: newer concepts in thrombosis and its role beyond thrombosis and hemostasis.Cardiovascular diagnosis and therapy · 2018Review
- NR4A1 Promotes Cerebral Ischemia Reperfusion Injury by Repressing Mfn2-Mediated Mitophagy and Inactivating the MAPK-ERK-CREB Signaling Pathway.Neurochemical research · 2018Article
- Therapeutic effect of Sirtuin 3 on ameliorating nonalcoholic fatty liver disease: The role of the ERK-CREB pathway and Bnip3-mediated mitophagy.Redox biology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
Identification of target molecules specific for angiogenic vascular endothelial cells (VEC), the inner layer of pathological neovasculature, is critical for discovery and development of neovascular-targeting therapy for angiogenesis-dependent human diseases, notably cancer, macular degeneration and endometriosis, in which vascular endothelial growth factor (VEGF) plays a central pathophysiological role. Using VEGF-stimulated vascular endothelial cells (VECs) isolated from microvessels, venous and arterial blood vessels as in vitro angiogenic models and unstimulated VECs as a quiescent VEC model, we examined the expression of tissue factor (TF), a membrane-bound receptor on the angiogenic VEC models compared with quiescent VEC controls. We found that TF is specifically expressed on angiogenic VECs in a time-dependent manner in microvessels, venous and arterial vessels. TF-targeted therapeutic agents, including factor VII (fVII)-IgG1 Fc and fVII-conjugated photosensitizer, can selectively bind angiogenic VECs, but not the quiescent VECs. Moreover, fVII-targeted photodynamic therapy can selectively and completely eradicate angiogenic VECs. We conclude that TF is an angiogenic-specific receptor and the target molecule for fVII-targeted therapeutics. This study supports clinical trials of TF-targeted therapeutics for the treatment of angiogenesis-dependent diseases such as cancer, macular degeneration and endometriosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.